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ABSTRACT 
Background: Malignant mesothelioma (MM) is a highly aggressive, incurable asbestos-induced cancer for which treat- 
ment options are limited. Surgical resection can reduce tumour burden, but patients ultimately succumb to disease due 
to reoccurrence of unresectable tumour, highlighting the need for new treatment modalities. In this study we describe 
the use of an easily translatable heat shock (HS) treated autologous tumour lysate vaccine and discus its potential appli- 
cation as an adjunct therapy for treating MM. Methods: Heat shocked autologous tumour lysate (HSL) vaccine was 
generated from AE17sOVA mesothelioma cells and tested for its ability to act as a protective or therapeutic vaccine in a 
murine tumour model. Vaccine efficacy was assessed by tumour growth/survival of vaccinated mice and FACS analysis 
used to assess DC maturation and trafficking from vaccine site to draining lymphnodes (dLN). Results: Mice vacci-
nated prior to tumour challenge with HS lysate induced protection in 40% of mice and caused a significant delay in tu-
mour progression in remaining mice. Vaccine dose-response experiments showed that HS lysate was at least a log more 
efficient at retarding tumour growth and promoting survival than untreated lysate. HS and untreated lysate were equally 
effective at maturating DCs, but HS lysate improved trafficking of vaccine-site DCs to draining lymph nodes (dLN). 
Direct intratumoural injection of HS lysate significantly delayed tumour progression. Conclusions: HS treatment of tu- 
mour lysate improved vaccine immunogenicity, was associated with DC maturation, increased DC trafficking to dLNs 
and delayed tumour growth, particularly when administered intratumourally. Heat shocking autologous tumour cells is a 
simple and easily translatable approach to generate an immunogenic lysate vaccine with significant prophylactic and 
therapeutic effects. Coupling intratumoural HS vaccines with conventional therapies such as surgery may improve pa-
tient responses for otherwise refractive tumours. 
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1. Introduction 
Tumour vaccine strategies in recent years have concen- 
trated on the identification and isolation of specific anti- 
gens from a patients tumour and using the peptides either 
to stimulate exogenous DCs prior to adoptive transfer, or 
as a “typical” subcutaneous vaccine with adjuvant. Similar 
concepts have been adopted in the use of autologous heat 
shock protein (HSP)-peptide complexes isolated from 
patient tumour samples, with promising tumour-specific, 
CD8+ T lymphocyte observations and expansion of the 
natural killer (NK) cell population in immunized patients 
[1,2]. However, these methods of vaccine production are 
both time consuming and labour-intensive. Heat-shocking 
cells increases their immunogenicity [3-5]. Thus, an effi- 
cient and potentially enhanced immunogenic method of 
delivering HSP tumour vaccines may be to source auto- 
logous tumour cells via resection, and induce HSP produ- 
ction in the laboratory prior to vaccination at either a pre- 
adjuvant-conditioned site (to promote DC migration to the 
vaccination site) or in combination with another adjuvant. 
HSP immunogenicity was originally observed due to 
the stimulation of a robust T cell response against tissues 
from which the HSPs had been sourced and purified [6]. 
Later, rejection of tumour was observed when directly 
injected with HSPs purified from autologous tumour cells 
in-vitro [7]. HSP released from necrotic cells are known 
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to be efficiently endocytosed, mediated by receptors on 
antigen presenting cells (APCs) [8] and these HSP-peptide 
complexes are presented through the MHC class I antigen 
(Ag) presentation pathway. Aside from the crosspresenta- 
tion capabilities of HSPs through various recaptors on APCs 
[9], they have also been attributed with an adjuvant effect 
that is independent of peptide and associated with stimula-
tion of Toll like receptor 2 (TLR-2) or TLR-4 with the 
non-peptide bound HSP [10,11]. This response involves an 
upregulation of inflammatory cytokines including inter-
leukin-12 (IL-12) and co-stimulatory molecules, with 
concomitant activation of NK cells and other immune 
system cells and co-stimulatory molecules [12-15]. 
In this study, we investigated the possibility of en- 
hancing the immunogenicity of an autologous MM vac- 
cine by enriching cell lysates with HSPs using a heat- 
shocking protocol prior to lysis. We also examined the 
DC-activating properties and therapeutic potential of this 
heat-shocked MM vaccine. 
2. Materials and Methods 
2.1. Reagents and Mice 
All reagents were purchased from Sigma (Castle Hill, 
NSW, Australia) unless stated otherwise. Female C57Bl/6 
(H-2Kb) mice aged between 6 and 8 wks were obtained 
from the Animal Resources Centre (Murdoch, Western 
Australia) and maintained under standard SPF housing 
conditions. Animal experiments were carried out acco- 
rding to protocols approved by the University of Western 
Australia Animal Ethics Committee. 
2.2. Tumour Cell Lines 
The murine MM cell line AE17 was derived from the 
peritoneal cavity of C57Bl/6J mice injected with asbestos 
fibres (crocidolite) and stably transfected with the natu-
rally occurring secreted form of OVA (AE17sOVA) un-
der the control of the human β-actin promoter as de-
scribed [16]. The AE17sOVA cell line was maintained in 
RPMI 1640 media (Invitrogen, Victoria, Australia) sup-
plemented with 10% FCS (CSL, Victoria, Australia), 
20mM HEPES (Life Technologies), pH 7.4, 48 mg/L 
gentamicin (Pharmacia and Upjohn, Western Australia, 
Australia), 60 mg/L benzylpenicillin (David Bulls Labo-
ratory, Victoria, Australia) and 0.05 mM 2ME (Merck, 
West Point, PA). Supplemented with 400 µg/L of the 
neomycin analogue G418 (Geneticin: Invitrogen). Cells 
were cultured at 37˚C in a 5% CO2 atmosphere and pas-
saged when 70% confluent. 
2.3. Heat Treatment of Tumour Cells and Lysate 
Preparation 
Monolayers of AE17sOVA cells in T175 flasks were 
incubated for 1 h at 43˚C using a water bath. The cells 
were then incubated in fresh media at 37˚C (5% CO2) for 
3 hr. Cells were harvested with trypsin and centrifuged at 
400 × g for 7 min, media was removed and the cells were 
washed × 2 with PBS. After a cell count using a haemo-
cytometer, the cells were adjusted to, either 1 × 106, 1 × 
107, or 1 × 108 cells/100 L in PBS in cryovials and 
freezethawed in liquid N2/37˚C water bath for 5 cycles. 
Cryovials were then stored at –80˚C until use. 
2.4. Hsp70 Quantification in Tumour Cell Lysate 
The amount of inducible Hsp70 induced by heat-shocking 
of cultured AE17sOVA cells was quantified using an 
Hsp70 ELISA kit according to the manufacturer’s inst- 
ructions (Stressgen Bioreagents, Vancouver, BC). Briefly, 
a cell pellet of 1 × 106 tumour cells was treated with ex- 
traction buffer in the presence of protease inhibitors and 
the cell suspension incubated on ice for 30 min. Extracts 
were centrifuged at 21,000 × g for 10 min/4˚C. The su- 
pernatant was removed and assayed by quantitative san- 
dwich ELISA, which does not cross-react with other 
Hsp70 family members (e.g. Hsc70). Hsp70 levels were 
also visualised after western blot. Freeze-thawed lysates 
of AE17sOVA cells (untreated or heat-shocked), a posi-
tive control HeLa cell extract (BD Biosciences, New 
Jersey, USA), and recombinant Hsp70 (Stressgen Bio-
reagents) were resolved by SDS-PAGE on a 12% (w/v) 
acrylamide Tris-HCL pre-cast gel as per manufacturer’s 
instructions (Bio-Rad Laboratories, Australia). Proteins 
were transferred to nitrocellulose membrane before stain- 
ing with mouse anti-human Hsp70 clone 7 (cross-reactive 
with mouse, BD Biosciences, New Jersey USA) followed 
by rabbit-anti-mouse IgG-HRP secondary antibody (In- 
vitrogen Pty Ltd, Carlsbad CA) and ECL substrate (Pierce, 
Thermo Scientific, Rockford IL) prior to film exposure & 
development. 
2.5. Protective and Therapeutic Vaccine 
Experiments 
For single vaccination experiments, mice received 100 l 
of untreated or heat-shocked tumour lysate (102 to 108 
cells/dose depending on experiment) in the left flank by 
subcutaneous (s.c.) injection. For multiple vaccination 
experiments mice received 3 doses of either untreated or 
heat-shocked lysate vaccine (107 cells/dose) in the right 
flank in one week intervals. Mice injected with saline 
alone were used as controls throughout. All mice were 
challenged 14 days after the last dose of vaccine by s.c. 
injection in the right flank with 1 × 106 viable AE17- 
sOVA tumour cells, unless otherwise stated. Subsequent 
tumour growth was monitored by taking two perpen- 
dicular diameters using microcalipers. Mice were sacri- 
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ficed when tumour dimension reached 100 ± 5 mm2. For 
therapeutic treatments, mice were first inoculated with 1 
× 106 viable AE17-sOVA tumour cells in the right flank 
on day 0 and solid tumours allowed to establish for 10 
days (reaching approximately 4 mm2). Tumour-bearing 
mice then received a single 100 l injection of heat- 
shocked lysate vaccine (107 cells/dose) either in the opp- 
osing flank or directly into the tumour itself, and tumour 
growth monitored as above. 
2.6. DC Culture and Stimulation 
Bone-marrow-derived DC (BMDC) was generated using 
recombinant murine granulocyte/macrophage-colony sti- 
mulating factor (GM-CSF; Prospec-Tany, Rehovot, Is- 
rael) as described [17]. After 10 days in culture, BMDC 
were exposed for 24 h to either; saline, lipopolysaccha- 
ride (LPS; 100 ng/ml), heat-shocked or untreated tumour 
lysates (equivalent to 5 × 106 tumour cells) in Teflon 
24-well inserts (Savillex, Mn, USA) at 1 × 106 BMDC 
per well. BMDC were then washed twice with PBS and 
stained with FITC-anti-mouse CD11c (eBioscience, San 
Diego, CA) along with either; PE-conjugated anti-mouse 
CD80 or CD86 (eBioscience), or MHC class II (I-Ab; 
clone TIB120, prepared in house). Appropriate FITC and 
PE-conjugated IgG isotypes were used as controls. Cells 
were acquired on a FACScalibure flow cytometer and 
data analysed using CellQuest and FlowJo software. 
2.7. In Vivo Tracking of Vaccine-Site DC Migration 
Mice (5 per group) were vaccinated s.c. with either heat- 
shocked AE17sOVA lysate or untreated lysate (107 tu- 
mour cells/dose), or with saline as a control. Eight hours 
later, mice received 25 M of cell tracker blue (Invitro- 
gen) s.c. in 100 L saline into the same site. After a fur-
ther 12 h, mice were sacrificed and the inguinal and axil- 
lary lymph nodes draining the injection site along with 
the contralateral non-draining lymph nodes were then 
taken for analysis. A cell suspension was prepared as 
described [18] and stained with PE-anti-mouse CD11c, 
TriColor-anti-mouse CD8, and APC-streptavidin/biotin- 
anti-mouse CD11b and biotin-anti-mouse Dec205, co- 
stained with FITC-streptavidin (all from eBioscience). 
Appropriate fluorophore-conjugated IgG isotypes were 
used as controls. Cells were acquired and analysed by 
FACS as above. 
2.8. Statistical Analysis 
Student’s t test was used to measure significance be- 
tween two individual groups, Log rank analysis was per- 
formed on survival curves. All analysis was performed 
using Graph Pad Prism Software (Graph Pad Software Inc., 
CA, USA) and a P value < 0.05 considered signifycant. 
3. Results 
3.1. Heat-Shocking Induces Hsp70 Expression 
in AE17sOVA Cells 
The susceptibility of the ovalbumin-transfected malign- 
nant mesothelioma cell line (AE17sOVA) to heat-induced 
stress was examined by measuring the levels of Hsp70 by 
western blot and ELISA in the untreated and heatsho- 
cked lysates. Hsp70 was undetectable by ELISA in the 
untreated lysate and was only observed at low levels by 
western blot (Figure 1(a)). Heat-shocking for 1 h at 43˚C 
induced the expression of Hsp70 in AE17sOVA to a 
level of 250 ng/106 cells, similar to that observed in hu-
man mesothelioma cell lysate (p. 42; Figure 1(b)). Heat- 
shocking of a Balb/c-restricted mesothelioma cell line,  
 
 
(a) 
 
(b) 
Figure 1. Induction of Hsp70 expression in AE17sOVA fol- 
lowing heat-shock. Monolayers of AE17sOVA cells were 
incubated at 37˚C (untreated) or heat shocked at 43˚C for 1 
hour in a water bath prior to recovery in fresh media for 
3 hrs at 37˚C. (a) Hsp70 specific western blot analysis dem- 
onstrating an increase in Hsp70 expression in cell lysates 
following heat shock treatment relative to untreated con- 
trols; (b) Hsp70 specific ELISA demonstrating that the level 
of Hsp70 protein expression increased upon heat shock 
treatment. Similar levels of Hsp70 was observed between 
AE17sOVA and human mesothelioma cell lysates, but not 
AB1-HA (Balb/c mesothelioma) cell lysate following heat 
shock treatment. 
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AB1-HA [19], also induced detectable Hsp70 expression 
but at 3-fold lower levels than AE17sOVA. 
3.2. Heat-Shocked AE17sOVA Cell Lysate is 
More Effective at Delaying and Preventing 
Tumour Progression 
To determine the effectiveness of both untreated and heat- 
shocked tumour cell lysate vaccines at protecting against 
tumour growth, mice were vaccinated once, subcutane- 
ously with increasing doses of either vaccine and then 
challenged 14 days later with viable AE17sOVA tumour 
cells. Both vaccines formulations were partially protec-
tive (20% - 40% long-term survival) at the highest dose 
tested (108 cells/dose; Table 1). However, only the heat- 
shocked cell lysate vaccine was still protective when a 
10-fold lower dose was used, although no protection was 
observed for doses lower than this. Both vaccines also 
significantly delayed tumour growth (~2-fold) in unpro- 
tected mice when using 108 cells/dose. Here again, the 
heat-shocked cell lysate vaccine was approximately a 
log-fold more effective than the untreated cell lysate with 
significant delays in tumour growth observed using as 
little as 106 cells/dose (Table 1). Vaccination with puri- 
fied ovalbumin in incomplete Freund’s adjuvant (IFA) 
had no effect on survival or growth of AE17sOVA (Ta- 
ble 1) despite promoting robust OVA-specific CD8 re- 
sponses (data not shown). Interestingly, vaccination of 
BALB/c mice with heat-shocked AB1-HA lysate 
(107cells/dose) had no effect on survival or tumour 
growth after AB1-HA challenge (data not shown), con- 
sistent with the lower Hsp70 response observed in this 
line (Figure 1(b)). 
3.3. Multiple Vaccinations Do Not Improve 
Resistance to Challenge 
To ascertain if a prime-boost strategy would be more 
effective at promoting survival against AE17sOVA, mice 
received 3 vaccine doses (107 cells/dose s.c.) one week 
apart, prior to tumour challenge. Multiple vaccinations 
with heat-shocked cell lysate had no added benefit on 
survival over a single vaccination, and multiple vaccine- 
tions with untreated cell lysate were still unable to pro- 
mote survival (Figure 2(a)). Emergence of tumour in 
unprotected mice receiving multiple doses of heat-shocked 
cell lysate was also significantly delayed (~20 days; Fig- 
ure 2(b)). However, unlike tumour kinetics in the single- 
dose experiments, once tumours did emerge they appeared 
to grow more rapidly than in saline or untreated cell lys- 
ate vaccinated mice (Figure 2(b)). 
3.4. Both Heat-Shocked and Non Heat-Shocked 
Lysate Vaccines Induce Maturation 
of BMDC 
To determine if the increased potency of HSL vaccina-
tion was due to adjuvant effects on DCs we measured the 
level of maturation induced by HSL and lysate on 
BMDC in-vitro, BMDCs were stimulated 5 to 1 with 
equivalent tumour cells for 24 hr and then stained for 
MHC and co-stimulatory molecules. Unstimulated BMDC 
had relatively low levels of CD80, CD86 and MHC 
 
Table 1. Effect of dose in the efficacy of lysate and heat shocked lysate vaccines. 
Vaccine Vaccine dose (cells/dose) 
Mean tumour kinetics 
(days to 100 mm2)† 
Significance 
*p < 0.05 
% Protection 
(n) 
Saline NA 25.2 ± 0.8 ns 0 (31) 
OVA/IFA [200 g/ml i.p.] 24.33 ± 0.7 ns 0 (12) 
108 41.75 ± 5.4 * 20 (5) 
107 30 ± 1.3 * 0 (15) Lysate 
106 26.7 ± 0.5 ns 0 (7) 
108 39.6 ± 4.9 * 40 (5) 
107 36.2 ± 1.9 * 40 (13) HS-lysate 
106 36.0 ± 0.0 * 0 (4) 
105 21.4 ± 2.8 ns 0 (5) 
104 21.6 ± 0.9 ns 0 (5) HS-lysate (low dose) 
102 23.2 ± 2.3 ns 0 (5) 
Naïve C57Bl/6 mice received a single subcutaneous vaccination of either untreated or heat shocked lysates at indicated doses prior to subcutaneous challenge 
with 1 × 106 viable AE17sOVA tumour cell 14 days later. Both vaccines significantly delayed tumour development in comparison to untreated controls. How-
ever, only heat shocked cell lysate was 10-fold more efficient at protecting mice against tumour challenge relative to untreated lysate. †Data shown are the 
mean (±SEM) of the time (days) taken for tumours to reach 100 mm2, animal numbers (n) are as shown in the protection column. 
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(b) 
Figure 2. Multiple HSL vaccination does not improve resis-
tance to tumour challenge. (a) Naïve C57Bl/6 mice were 
vaccinated subcutaneously with three doses of either un-
treated or heat-shocked cell lysates on days 0, 7 and 14 (1 × 
107 cells/dose) prior to subcutaneous challenge with viable 
AE17sOVA tumour cells on day 28. No additional survival 
benefit was observed for mice receiving multiple vaccina-
tions versus those that received single vaccination; (b) Mice 
that ultimately failed to respond heat shocked lysate vacci-
nation demonstrated significantly delayed tumour growth 
relative to saline and untreated lysate controls; although 
once tumour began to develop it did so at a much faster rate 
relative to control mice. 
 
class II (Figure 3(a)). Stimulation with lysate caused a 
marked upregulation in expression of all three surface 
markers. Stimulation with HSL also induced upregulation 
of CD80, CD86 and MHC class II but responses were not 
higher than with normal lysate. 
3.5. Heat-Shocked AE17sOVA Lysate Induces 
Local DCs to Preferentially Migrate to 
Draining Lymph Node 
We next investigated the kinetics involved in DC traf-
ficking to lymph nodes, subsequent to exposure to HSL. 
Mice were vaccinated s.c. with 1 × 107 HSL followed 8 h 
later by treatment of the injection site with cell tracker 
blue dye in order identify migrating DCs. HSL-vaccinated 
mice showed a four-fold increase in the proportion of 
cells trafficking from the vaccine-site in the draining 
lymph node compared to those treated with lysate, and 
over a seven-fold increase compared to saline treated 
mice (Figure 3(b)). Trafficking cells were CD11c+ and 
CD8– (Figure 3(b)) and expressed CD11b and Dec205 
(data not shown) consistent with a migratory DC profile 
[20]. Together, these data indicate that HSL and lysate 
vaccines can induce DC activation but that HSL treat- 
ment promotes superior recruitment of activated DCs in 
the draining lymphnodes. 
3.6. Prophylactic Vaccination Promotes Long 
Term Immunological Protection 
We next tested whether HSL vaccination could promote 
long term immunological protection (i.e. memory) against 
AE17sOVA tumour. Surviving mice from single vacci- 
nation experiments (Table 1, n = 4) were subcutaneously 
rechallenged on the contra-lateral flank with 1 × 106 vi- 
able tumour cells, 100 days after the initial tumour chal- 
lenge (i.e. d14 + 100). On the same day, naïve control 
mice were inoculated with 1 × 106 AE17sOVA cells, 
having received saline vaccination 14 days earlier. Con-
trol mice succumbed to tumour growth by day 30, post 
tumour challenge, while 100% of HSL vaccinated mice 
survived tumour rechallenge with no visible tumours (Fi- 
gure 4). 
3.7. Therapeutic Intratumoural Injection of HSL 
Vaccine Delays Tumour Growth, but Does 
Not Protect against Tumour Challenge 
To determine whether AE17sOVA HSL vaccination 
could protect against tumour challenge in a therapeutic 
setting, groups of 5 mice were first inoculated s.c. on day 
0 with 1 × 106 viable AE17sOVA cells and then treated 
on day 10 with either AE17sOVA HSL or untreated 
AE17s OVA lysate equivalent to 1 × 107 cells, or with 
saline (control). Tumour growth was consistent between 
all groups with all mice succumbing to tumours by day 
35 when vaccines were administered subcutaneously 
(Figure 5(a)). Interestingly, when vaccines were admin-
istered intratumorally (i.t.), we observed a significant 
delay in tumour growth (p < 0.05; ≥1.3-fold) in HSL 
vaccinated mice relative to other groups. However, 
therapeutic i.t. vaccination failed to eliminate AE17sOVA 
tumour development (Figure 5(b)). 
4. Discussion 
Aggressive surgery with adjunct chemotherapy or radio- 
therapy is one treatment regimen used for malignant 
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(a) 
 
(b) 
Figure 3. Heat shocked lysate promotes equivalent level of maturation as lysate-stimulated BMDC. (a) Bone marrow derived 
dendritic cells were stimulated in vitro with heat-shocked or non-heat-shocked AE17sOVA lysate (equivalent to 5:1 tumor 
cells/DC) of left unstimulated for 24 hrs prior to staining for surface marker expression of CD11c and the DC maturation 
markers CD80, CD86 and MHC class II. Dark grey shaded histogram = isotype control; light grey shaded histogram = un-
stimulated; grey line = untreated lysate; black line = heat shock treated lysate; (b) Vaccine-induced DC trafficking to lym-
phnodes. Mice were injected with either heat-shocked lysate or untreated lysate (both 107 cells/injection) for 8 h. Cell Tracker 
Blue dye was then added to the injection site and after a further 12 h the number of “dye” containing CD11c+ DCs in the 
draining lymph node determined by flow cytometry after first pooling lymphnodes from 5 mice per group. 
 
 
 
Figure 4. Prophylactic vaccination promotes long term im-
munological protection against tumour rechallenge. Sur-
viving mice from single vaccination experiments (Table 1, n 
= 4) were rechallenged with 1 × 106 viable AE17sOVA cells 
(s.c) on the contra-lateral flank 100 days after initial tu-
mour challenge. Control mice (n = 2) received tumour chal-
lenge 14 days post saline vaccination. 100% of HSL vacci-
nated mice survived tumour rechallenge while all control 
mice succumb to tumour by day 30. 
mesothelioma with the intent of prolonging life, espe-
cially in younger patients. Yet they are seldom curative. 
Most MM patients experience a high recurrence rate of 
local disease and succumb within 9 to 12 months of di-
agnosis [21] highlighting the need for improved adjuvant 
therapies that will target residual or metastatic disease 
and improve survival after surgery. Immunotherapies, 
such as tumour vaccines have emerged as a therapeutic 
option for the management of cancer patients. These 
vaccines have shown most potential when targeted to- 
ward relatively immunogenic cancers with known tu-
mour antigens such as melanoma and prostate cancer [22, 
23]. However, despite these limited clinical successes, 
cancer vaccines to date have not lived up to their poten- 
tial as many cancers, such as MM, are poorly immuno- 
genic and their tumour associated antigens (TAAs) re- 
main uncharacterised. In the absence of known tumour 
antigens, the use of autologous tumour lysates have pro- 
vided an alternative vaccine approach, as by definition 
they should contain all relevant TAAs within them (re- 
viewed in [24]). Hyperthermic treatment of tumour lys-
ates can enhance their immunogenic potential due to the 
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(a) 
 
(b) 
Figure 5. Therapeutic vaccination fails to protect against tumour rechallenge. Naïve mice were inoculated subcutaneously 
with 1 × 106 viable AE17sOVA cells 10 days prior to receiving saline control, untreated lysate or heat shock lysate via subcu-
taneous (s.c) or intratumoral (i.t) vaccination. (a) Consistent tumour growth was observed between all groups with all subcu-
taneously vaccinated mice succumbing to tumour by day 35; (b) Intratumoral therapeutic vaccination with heat shocked lys-
ate significantly delayed tumour development relative to control or subcutaneous vaccination groups, but failed to protect 
against overall tumour development. 
 
ability of heat shock proteins to promote cross presenta- 
tion of antigenic peptides [3-5], a necessary step for in-
ducing anti-tumour immunity. In contrast to previous 
studies that utilised HSP-peptide complexes purified from 
tumour lysates [1,2,25], we investigated whether a sim-
ple heat-shock protocol could be used to enrich MM tu-
mour cells with HSPs prior to lysis and to test whether 
HS treatment enhanced the immunogenicity of the re-
sulting tumour lysate vaccine. 
Our data demonstrate that HS treatment of tumour 
cells results in increased Hsp70 expression equivalent to 
that observed in human mesothelioma cells. When lys- 
ates made from these cells were used as vaccines, we 
observed significantly improved protection and delayed 
tumour development. These results are consistent with 
previous reports demonstrating the anti-tumour proper-
ties of tumour derived HSP-peptide complexes [1,2,5]. 
Interestingly, both HSL and untreated lysate were able to 
induce similar levels of BMDC maturation following 
vaccination, although HSL showed enhanced recruitment 
of local DCs to the draining lymph node (dLN) compared 
to untreated lysate. Cross presentation of tumour antigen 
by DCs to T cells is essential for the development of an- 
titumor immunity and the increased DCs trafficking to 
the dLN plus the ability of HSPs to more efficiently 
chaperon antigenic peptides for presentation [5,25] may 
explain the enhanced immunogenicity of the HSL vac- 
cine. This has been exploited in a recent study using DC 
vaccines fused with purified HSP complexes to enhance 
DC vaccination efficacy [26]. However, these protocols 
are generally labour intensive, and require substantial 
time commitments and cost associated with preparation 
of vaccine components. Our data demonstrates that a 
simple, inexpensive method of enriching HSP in tumour 
lysates is comparable to more costly and time consuming 
autologous lysate preparation methods. Importantly, we 
have previously demonstrated the feasibility of this 
preparation method for treating MM [27]. 
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In the prophylactic setting, a single s.c dose of the HSL 
vaccine was sufficient to induce long term immunological 
memory and protect against subsequent tumour rechal-
lenge. However, as with many tumour immuno-therapies 
the s.c HSL vaccine failed to protect if administered 
therapeutically. Importantly, when HSL was used as a 
therapeutic vaccine administered intratumourally it was 
able to significantly delay tumour growth. Thus directly 
delivered HSL vaccines could boost local anti-tumor 
responses, at possibly the most relevant site. We ob- 
served a similar result in an earlier study using our MM 
model following i.t delivery of interleukin-2 (IL-2) plus 
anti-CD40 combined adjuvant immunotherapy [28]. Here, 
i.t. delivered IL-2 + anti-CD40, induced local inflamma- 
tion that prompted tumour destruction and release of au- 
tologous TAA, which in turn promoted the development 
of a systemic anti-tumour immune response. These results 
demonstrate the potential for locally administered adju- 
vant immunotherapies to manipulate the tumour milieu 
such that the tumour can now become its own vaccine. 
This raises the possibility of using HS treated tumour 
lysates to complement current treatment options for the 
management of solid malignancies like MM. Thermal 
treatment modalities such as radio frequency ablation (RFA), 
microwave ablation (MVA) and cryoablation have been 
used to treat solid malignancies, including lung cancers 
[29-31]. RFA induces hyperthermia within the tumour 
resulting in necrotic cell death and the release of endo- 
genous adjuvants such as Hsp70 [32], which can then 
promote a primary anti-tumour response. Indeed, the com- 
bination of HSL pulsed autologous DC vaccine with RFA 
was recently shown to abrogate tumour recurrence [33], 
demonstrating the practical advantage of using HS treat- 
ment of autologous vaccines as an adjuvant therapy in 
combination with standard treatment modalities to target 
residual disease. 
5. Conclusion 
In conclusion, we have shown that heat shocking of 
autologous tumour cells is a simple and translatable ap-
proach to generate an immunogenic lysate vaccine with 
significant prophylactic and therapeutic effects when de- 
livered intratumourally. Coupling intratumoural autolo- 
gous heat shocked vaccines with conventional therapies 
such as chemotherapy and surgery may improve patient 
responses for otherwise refractive tumours such as ma-
lignant mesothelioma. 
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